Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Tjalf ZiemssenAnn D BassRegina BerkovichGiancarlo ComiSara EichauJeremy HobartSamuel F HunterChristopher LaGankeVolker LimmrothDaniel PelletierCarlo PozzilliSven SchipplingLivia SousaAnthony TraboulseeBernard M J UitdehaagBart Van WijmeerschZia ChoudhryNadia DaizadehBarry A Singernull nullPublished in: CNS drugs (2021)
NCT00530348; NCT00548405; NCT00930553; NCT02255656.